Falls Church, VA – Retension Pharmaceuticals has announced the appointment of Alison Schecter as Chief Medical Officer. About Retension Pharmaceuticals: Retension Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing effective treatments to optimize blood pressure and improve cardiovascular health. Centered on addressing hypertension and serious cardiovascular diseases, the company is advancing innovative therapies for patients whose blood pressure remains uncontrolled or resistant despite existing treatments. Its work is driven by a commitment to improving outcomes for the large population of individuals living with difficult-to-treat hypertension, reflecting a specialized focus within the cardiovascular therapeutic area. As a biopharmaceutical developer, Retension Pharmaceuticals operates at the intersection of cutting-edge science and clinical research, translating novel mechanisms of action into potential new standards of care for cardiovascular patients. Through its targeted approach to blood pressure control and cardiovascular health, the company positions itself as an emerging player in the hypertension treatment landscape.

For more information visit: https://www.retensionpharmaceuticals.com/

Retension Pharmaceuticals
1104 West Broad Street #1029
Falls Church, VA 22046
Phone: 703-624-2024
LinkedIn: https://www.linkedin.com/company/retension-pharmaceuticals/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved